Are high drug prices for hematologic malignancies justified? A critical analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Are high drug prices for hematologic malignancies justified? A critical analysis

Published:2015-06-23 Issue:19 Volume:121 Page:3372-3379
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Chhatwal Jagpreet¹,Mathisen Michael²,Kantarjian Hagop³

Affiliation:

1. Department of Health Services Research; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Epocrates Medical Information; AthenaHealth San Francisco California

3. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.29512/fullpdf

Reference56 articles.

1. High cancer drug prices in the United States: reasons and proposed solutions;Kantarjian;J Oncol Pract,2014

2. Why are cancer drugs so expensive in the United States, and what are the solutions?;Kantarjian;Mayo Clinic Proc,2015

3. http://www.census.gov/content/dam/Census/library/publications/2014/demo/p60-249.pdf 2015

4. Henry J http://kaiserfamilyfoundation.files.wordpress.com/2013/01/8170.pdf 2015

5. Henry J http://kff.org/medicare/fact-sheet/medicare-at-a-glance-fact-sheet/ 2015

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disparities in mortality risk after diagnosis of hematological malignancies in 185 countries: A global data analysis;Cancer Letters;2024-07

2. Outcome of Philadelphia chromosome‐positive chronic myeloid leukemia in the United States since the introduction of imatinib therapy—The Surveillance, Epidemiology, and End Results database, 2000–2019;Cancer;2023-09-28

3. Discarded Targeted Oral Anticancer Medication—A Hard Pill to Swallow?;JAMA Oncology;2023-09-01

4. Career disruption and limitation of financial earnings due to cancer;JNCI Cancer Spectrum;2023-06-16

5. The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA;The Lancet Haematology;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3